Metis Global Partners LLC grew its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 17.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 119,251 shares of the biopharmaceutical company’s stock after buying an additional 17,479 shares during […]
Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
Gallacher Capital Management LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 57.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,857 shares of the biopharmaceutical company’s stock after purchasing an additional 2,855 shares during the quarter. Gallacher Capital […]
ARS Wealth Advisors Group LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 92.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,199 shares of the biopharmaceutical company’s stock after selling 103,371 shares during the period. ARS […]
First Horizon Advisors Inc. increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,408 shares of the biopharmaceutical company’s stock after buying an additional 2,075 shares during […]